Finoriq research workspace
Immunovant, Inc. (IMVT) Institutional Holdings & 13F Ownership
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the. Review IMVT institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Company
- Immunovant, Inc. (IMVT)
- Ticker
- IMVT
- Market Cap
- $8.2B
- Latest Price
- $39.91
- Industry
- Biotech & Pharma
Immunovant, Inc. (IMVT) Top Institutional Holders
Top current 13F holders indexed for Immunovant, Inc. (IMVT). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | David EinhornCIK 0001489933 | $2.3M | 0.07% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.